July 25, 2023
Mila and MoCA Cognition Partner up in Battle against Alzheimer’s and Dementia

Mila – Quebec AI institute, the world’s largest academic deep learning (DL) research center has established a partnership with MoCA Cognition, the company behind the world’s leading test for early detection of cognitive impairment. Together, they will apply artificial intelligence (AI) models to digital cognitive assessments used primarily for identifying Alzheimer’s Disease and dementia.

Read full article

June 08, 2023
Recorded Webinar: "The Effect of the APoE4 Gene on Neurocognitive Decline and Possible Mitigating Interventions"

On June 08, we hosted a virtual talk by Dr. Anne Marie Minihane.

Watch presentation and download the slides

May 31, 2023
Prevent the Hidden Costs of Head Trauma with Early, Effective Cognitive Testing

The costs of traumatic brain injuries (TBIs) — one of the leading causes of death and disability worldwide, with an estimated 69 million people newly affected each year — are enormous and often go unnoticed. In fact, TBIs are often referred to as “the silent epidemic” because the symptoms of brain injuries aren’t always apparent after an incident occurs.

Read full article

May 18, 2023
Recorded Webinar: "New Assistive Technologies in Dementia and MCI care"

On May 18, we hosted a virtual talk by Dr. Stephen Lee-Cheong.

Watch presentation and download the slides

May 01, 2023
Improving Outcomes in Cancer Patients and the Role of Screening for Cognitive Impairment

Global estimates suggest 17 million people are diagnosed with cancer each year. Up to 80% of these patients report confusion, memory lapses, attention deficits, and an overall feeling of mental fog. Most patients recover within a year of cancer treatment, but up to 35% of cancer survivors continue to experience lasting symptoms. Fortunately, early detection is helping clinicians understand the mechanisms and risk factors underlying cancer-related cognitive impairments. By identifying deficits and introducing tailored therapies as soon as possible, we can offer patients a better long-term prognosis.

Read full article

April 20, 2023
Recorded Webinar: “Hearing Loss & Dementia in Older Adults”

On April 20, we hosted a virtual talk by Dr. Alison R. Huang.

Watch presentation and download the slides

March 23, 2023
Recorded Webinar: “Dynamic Perceptual-Cognitive Functions in Aging and Cognitive Training Tools”

On March 23rd, we hosted a virtual talk by Dr. Jocelyn Faubert.

Watch presentation and download the slides

March 02, 2023
Renal Failure Patients Require Cognitive Testing to Improve Outcomes and Well-Being

Globally, 10% of the population is affected by Chronic Kidney Disease (CKD). In people ages 65-74, an estimated 1 in 5 men and 1 in 4 women have CKD. Prevalence is rising along with increases in hypertension, diabetes, and obesity. Recently, scientists drew connections between declining kidney function and dementia, highlighting the need for early cognitive testing to improve medical outcomes.

Read full article

February 16, 2023
Recorded Webinar: “Functional Genomics of Alzheimer’s And Novel Therapeutic Strategies ”

On February 16th, we hosted a virtual talk by Dr.Martin Kampmann.

Watch presentation and download the slides

January 20, 2023
How Screening for Cognitive Deficits Leads to Improved Substance Abuse Interventions

Substance abuse and withdrawal can trigger mental disorders that are temporary—lasting up to a month after abstinence—or more permanent. One study found that 31% of patients using alcohol, cannabis, or stimulants scored below the cognitive impairment threshold for memory and visuospatial abilities. Prevalence studies conducted at residential rehabilitation facilities have found 52 to 80% of patients checking in had some form of cognitive impairment.

Read full article

December 8, 2022
Recorded Webinar: “Forgetting Loved Ones: The Relationship between Loneliness, Anxiety and Cognitive Function”

On December 8th, we hosted a virtual talk by researcher Dr. Lindsay C. Kobayashi.

Watch presentation and download the slides

November 24, 2022
The Role of Cognitive Assessment in Comprehensive Depression Treatment

Before the COVID-19 pandemic, depression was already the leading cause of disability worldwide, and its reach only widened during many months of lockdowns and social isolation. According to the World Health Organization, the pandemic spurred a 25% increase in global prevalence of depression and anxiety. An estimated 280 million people around the world have depression, accounting for 3.8% of the global population.

Read full article

November 11, 2022

Dear Colleague,

There is an upcoming major policy change for the use of the MoCA test. This change aims to maintain MoCA test access for all clinicians who value this tool and hope to continue using it despite the training requirement.

We acknowledge that publicly operated institutions may not afford the required Training and Certification, so we have therefore added publicly operated institutions to the list of parties eligible for free access to the Training and Certification Program. Teachers, Students, and Academic Researchers have free access to the training since September 2021.

As of January 1, 2023, all publicly operated institutions will be able to create a free account to manage MoCA Training and Certification for their personnel.

We value the importance of the one-hour online MoCA Training and Certification program to standardize test administration and scoring, however we are also committed to accessibility, regardless of financial capacity to finance such training.

Our goal is to ensure that MoCA is available and useful for all clinicians, and we are confident that this policy change will respond to affordability concerns from publicly operated institutions.

We appreciate your ongoing trust in this tool, and we will continue our work to provide practical solutions to assess patient cognition and contribute to early detection of cognitive impairment.

Respectfully yours,

Ziad Nasreddine, MD FRCP(C)
MoCA Cognition
Cognitive Neurologist

November 10, 2022
Recorded Webinar: “Diabetes and Cognitive Impairment: Epidemiology, Mechanisms, Treatment, and Prevention”

On November 10th, we hosted a virtual talk by general internist, tenured Professor of Medicine, and Chief of the Division of General Internal Medicine at the Medical College of Wisconsin (MCW) Dr. Leonard Egede.

Watch presentation and download the slides

November 07, 2022
How Diabetes Affects Cognition—and What Can Be Done

Diabetes is most commonly diagnosed between the ages of 45 and 64. However, because the chance of having multiple comorbidities increases with age, the disease often appears alongside other conditions, which can complicate treatment and reduce successful patient outcomes.

Read full article

September 26, 2022
The Connection Between Vascular Health and Cognition

As suppliers of critical oxygen and nutrients to the brain, blood vessels can have a profound impact on cognitive health. When there’s an issue with a blood vessel—whether it be blocked, narrowed, or ruptured—brain cells can’t receive the oxygen and nutrients they need, causing them to die off. Cognitive functions can suffer as a result, in a phenomenon known as vascular dementia.

Read full article

September 22, 2022
Recorded Webinar: “Cardiorespiratory Fitness is Protective Against Alzheimer's Disease and Related Dementias”

On September 22nd, we hosted a virtual talk by neurologist, researcher, and Alzheimer’s expert Dr. Edward Zamrini.

Watch presentation and download the slides

August 22, 2022
Sensory Loss and Implications for Dementia Testing

Declines in sight and hearing are a natural part of aging, but they can also be associated with mild cognitive impairment and dementia. Some researchers believe dementia alters the way the brain interprets sensory data, while others suspect that the loss of eye and ear nerve impulses is what accelerates cognitive decline. More research is needed to clarify the relationship between dual sensory loss and dementia, but recent studies affirm the connection—and provide hope that early intervention can potentially slow or stop cognitive decline..

Read full article

July 11, 2022
How Low Literacy and Education Can Impact Patient Health Outcomes

Basic reading, writing, and counting skills are critical in our everyday lives, but many of us take these skills for granted. Around the world, there are still 773 million adults who lack basic literacy skills—and in the U.S, in particular, 21% of adults lack the English literacy skills necessary to make simple inferences, paraphrase, or compare and contrast information.
What are the consequences of low literacy and education, beyond poor reading comprehension? People who are illiterate are less likely to be employed than those who are, more likely to be incarcerated, and earn less on average. What’s more, a lack of literacy skills can result in lower self esteem and feelings of shame, as well as alienation from school and society. People with lower education levels also experience more factors that correlate with depression onset than those with higher education, including daily stressors, a lack of resilience, and low sense of control.

Read full article

June 15, 2022
Recorded Webinar: “Preventing dementia: What risk factors should we target and in whom?”

On June 15th, we hosted a virtual talk by prolific researcher in epidemiology Dr. Matthew Pase.

Watch presentation and download the slides

May 26, 2022
Recorded Webinar: “Increased Prevalence of Dementia and Neurological Complications in COVID-19 Survivors”

On May 26th, we hosted a virtual talk by prolific researcher, author, professor and neurologist Dr. Adnan Qureshi

Watch presentation and download the slides

May 25, 2022
Why Screening for COVID-19 Cognitive Impairment Matters

Though there have been more than half a billion reported cases of COVID-19 worldwide to date, we have much to learn about the underlying mechanisms of associated cognitive impairment.
Exploring COVID-19’s short- and long-term cognitive effects - The connection between severe illness and cognitive impairment has been well-established. Two-thirds of patients who spend time in the ICU develop cognitive effects from inflammation, changes in blood pressure, and medication side effects. However, most cases of post-viral cognitive impairment resolve naturally over the course of a few months.

Read full article

April 25, 2022
Telemedicine: A Post-COVID Necessity

As healthcare professionals, we have all experienced profound changes to the way we deliver services following the sudden onset of the COVID-19 pandemic. Telemedicine rose up out of necessity during lockdowns—its use in April 2020 was 78 times higher than the February 2020 baseline, according to McKinsey. Two years later, this trend persists: telemedicine use is still 38 times higher than pre-COVID levels, prompting McKinsey’s assertion that $250 billion in healthcare services could potentially be virtualized.
Telemedicine is more than a trend born out of convenience. It can be a lifeline for patients—expanding access to previously unavailable care and providing a comfortable, immediate, affordable, and satisfying experience. It can also be a lifeline for healthcare providers—helping us keep a closer eye on patients, improve health outcomes, and do more, with fewer resources.

Read full article

March 24, 2022
Recorded Webinar: “Alzheimer’s Disease Drug Development Pipeline: Innovations and New Directions” 

On March 24th, we hosted a virtual talk by world-renowned researcher, author, and neurologist Dr. Jeffrey Cummings.

Watch presentation and download the slides

December 2, 2021
Recorded Webinar: “Update on Remote Cognitive Assessment Tools for Detection of MCI in the Context of COVID Pandemic and Anti-Amyloid Alzheimer's Therapies”

On December 2nd, we hosted a virtual talk by Dr. Serge Gauthier, author of 2021 World Alzheimer Report.

As a neurologist, researcher, and professor, Dr. Gauthier dedicated decades to the etiology and treatment of Alzheimer’s disease and related dementias. His work has influenced ethical guidelines and study design globally, resulting in over 700 authored peer-reviewed articles.

Watch presentation and download the slides


October 26, 2021
Do You Avoid Common MoCA Errors?

With only 30 questions, usually completed in 10 to 12 minutes, MoCA can detect mild cognitive impairment with greater sensitivity than other cognitive assessment tools. MoCA’s efficiency and superior sensitivity have resulted in wide-spread adoption among various medical professions in clinical, academic, and research settings worldwide.

However, professionals of all backgrounds still risk committing common errors, which can include gestures, cues, additional attempts, drawing outside allotted space, and incorrect scoring.

At the MoCA Clinic and Institute, we receive hundreds of referrals for memory loss each year. We regularly repeat MoCA assessments on patients 1-2 months after a previous assessment was completed outside of our facility. We have observed significant differences in total scores (3-4 points on average, and up to 4-5 points in some cases) in at least 20% of patients.

The MoCA Clinic and Institute has therefore implemented important features to maximize consistency and accuracy among raters:

  • Instructions are provided with each official MoCA PDF downloadable from the MoCA website (mocacognition.com/paper/)
  • The mandatory Training & Certification module carefully details the intricacies of administration and scoring, while also explaining the cognitive domains and neuroanatomical correlation that MoCA assesses.

Complete common MoCA errors quiz now

We monitor the performance of the Training & Certification module by comparing pre- and post-training evaluation scores. In a sample of 1850 consecutive training sessions, our analysis has found a pronounced improvement of MoCA competency across professions, geographies, and levels of experience. Overall:

  • Only 33% of users scored a passing grade of 70% or higher prior to training, compared to 79% of users after training

Our observations are in line with the findings of Newman et al1, published in 2018, which noted significant errors in administration and scoring of cognitive assessments performed by highly educated clinicians and researchers.

A 2019 study2 from the Kirkhof College of Nursing looked specifically at MoCA use in dementia detection and found that better understanding of the test itself and related neuroanatomy resulted in improved diagnosis and patient care.

Furthermore, A 2018 study3 in The New Zealand Medical Journal demonstrated a knowledge gap in junior doctors administering and scoring MoCA. With specific training, their accuracy and consistency improved significantly.

For these reasons, and due to strong demand from healthcare organizations and professional associations, MoCA has developed and made mandatory a brief online Training and Certification program.

To learn more about MoCA’s official Training & Certification: https://mocacognition.com/training-certification/

(1)   Newman, C. G., Bevins, A. D., Zajicek, J. P., Hodges, J. R., Vuillermoz, E., Dickenson, J. M., … & Noad, R. F. (2018). Improving the quality of cognitive screening assessments: ACEmobile, an iPad‐based version of the Addenbrooke’s Cognitive Examination‐III. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 10(1), 182-187.

(2)  Sutton, F.F. (2019) Implementation of an evidence-based screening protocol to improve the diagnosis of dementia in a home-based primary care setting. Kirkhof College of Nursing. https://scholarworks.gvsu.edu/cgi/viewcontent.cgi?article=1090&context=kcon_doctoralprojects

(3)   Tromop-van Dalen, C., Thorne, K., Common, K., Edge, G., Woods, L. (2018) Audit to investigate junior doctors knowledge of how to administer and score the Montreal Cognitive Assessment (MoCA). The New Zealand Medical Journal, Vol 131, No. 147.

October 20, 2021
COVID-19: MoCA Superior to MMSE for Detecting Cognitive Decline
Read abstract
October 13, 2021
Recorded Webinar: "Sex Differences in Alzheimer's and Cognitive Screening"

On October 7th, we hosted a virtual talk by Dr. Maria Teresa Ferretti, co-founder of Women’s Brain Project.

Dr. Ferretti’s work as a neuroimmunologist and Chief Scientific Officer at the WBP has resulted in several scientific publications in leading journals, including Nature, Science, and PNAS.  Dr. Ferretti is a sought-after speaker, having completed three TEDx Talks and regular lectures and presentations at both scientific and lay public meetings. She is a faculty member of the Course for Advance Studies (CAS) on gender medicine at University of Zurich and the editor of the recent book ‘Sex differences in Alzheimer’s Disease

Watch presentation: “Sex Differences in Alzheimer’s and Cognitive Screening”


September 20, 2021
Dr. Nasreddine discusses cognitive screening with "Nice Speech Lady"

MoCA creator, Dr. Ziad Nasreddine was recently interviewed by Ms. Wilson Nice, a speech-language pathologist herself and the curator of www.NiceSpeechLady.com which offers practical resources and great content for medical SLP’s.

Watch their interesting discussion regarding cognitive screening:

Read full article
September 17, 2021
Certification now FREE for Students, Faculty, and Academic Researchers

We are pleased to announce that MoCA’s official Training & Certification program is now available at no cost for all students, faculty members, and academic researchers. Proof of academic status is required and must be submitted via our website

The move to free certification for academic groups—along with free MoCA PDF pages already available on the MoCA website—underlines our commitment to ensuring unrestricted access to MoCA, while maintaining consistency and accuracy.

August 24, 2021
Improved MoCA scores for patients with AD or VaD treated with BET Protein Inhibitor Apabetalone
Read abstract
August 17, 2021
MoCA correlates with hyperglycemia in hypertensive diabetic patients

From the authors [bold added]:

“To investigate the consequences of hyperglycemia and metformin in the clinical scenario, we recruited frail hypertensive patients and we evaluated their Montreal Cognitive Assessment (MoCA) scores, comparing them according to the glycemic status (normoglycemic vs. hyperglycemic) and the use of metformin. We enrolled 376 patients, of which 209 successfully completed the study. We observed a significant correlation between MoCA score and glycemia. We found that hyperglycemic patients treated with metformin had a significantly better MoCA score than hyperglycemic patients treated with insulin (18.32 ± 3.9 vs. 14.94 ± 3.8; p < 0.001). Our in vitro assays confirmed the beneficial effects of metformin on human brain microvascular ECs. To our knowledge, this is the first study correlating MoCA score and glycemia in frail and hypertensive older adults, showing that hyperglycemia aggravates cognitive impairment.

Read full article
July 27, 2021
Moca Recommended for Aducanumab Appropriate Use Criteria
Read full article
July 1, 2021
"MoCA is the most frequently used screening instrument in PD research and clinical practice"
Read abstract
June 14, 2021
Vortioxetine improves cognition in mild cognitive impairment
Read abstract
June 14, 2021
MoCA Recommended by CDC for Post-COVID Neurological conditions
Read full article
June 7, 2021
Breakthrough Alzheimer’s Drug Makes Early Detection More Important Than Ever

Dear Colleague,

On June 7, the FDA announced the historic fast-tracked approval of Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s disease. This is the first drug to target the pathophysiology of Alzheimer’s and significantly reduce amyloid beta plaque in patients.

There has not been an FDA-approved treatment for the disease since 2003, and we are tremendously delighted by this news.

MoCA Research & Innovation has been working with Biogen, and other major pharma, to not only test and validate treatment options –such as Aducanumab—but to also facilitate rapid comprehensive screening of MCI and early-stage Alzheimer’s among large populations.

Early detection of MCI/Alzheimer’s is imperative to ensure optimal management and outcome. And now, with novel treatments, progression of symptoms and disease conditions can be reduced or halted.

MoCA’s mission has always been to provide the most efficient assessment solutions for earliest diagnosis of MCI, and we are excited to share with you soon the most advanced versions we are working on.

Cheers to you, the medical community.

The MoCA Team

Read full article
April 17, 2021
MoCA best to predict medical decision-making capacity
Read abstract
April 14, 2021
Hyposmia associated with MCI in Covid-19 patients
Read abstract
March 31, 2021
Cognitive impairment may persist 6 months after Covid Infection
Read abstract
March 24, 2021
MoCA sensitive to detect Cannabis related cognitive impairment
Read abstract
March 21, 2021
MoCA useful for longitudinal follow-up of MCI and VCI
Read abstract
February 11, 2021
MoCA useful to detect MCI in patients with Mild Covid
Read abstract
February 5, 2021
T‐MoCA: A valid phone screen for cognitive impairment in diverse community samples
Read abstract
January 2, 2021
MoCA useful in detecting Covid-19 related cognitive impairment.
Read abstract
January 1, 2021
MoCA useful in detecting Covid-19 related cognitive impairment.
Read abstract
December 9, 2020
Utility of MoCA to Predict Amyloid Physiopathology in Mild Cognitive Impairment
Read abstract
November 2020
MoCA Superior to MMSE for Frailty Assessment
Read abstract
August 12, 2020
MoCA Recommended by the American Academy of Family Physicians
Read full article
July 2020
MoCA is the most discriminative tool for screening MCI in the PD population
Read abstract
March 2020
Remote MoCA Testing
Read full article
March 2020
MoCA Best screening test for hemodialysis patients
Read abstract
February 2020
Performing MoCA By Videoconference
Read full article
September 2019
MoCA recommended by AAN for Annual Cognitive Screening for Adults 65+
Read full article
August 2019
MoCA best predictor of cognitive progression in Parkinson
Read abstract
June 2019
Upcoming Mandatory Training for MoCA Testing

It is for our growing community of healthcare professionals that we are now requiring training and certification for test use. In an effort to reduce variability and ensure the highest accuracy, our training and certification program will become mandatory as of September 1, 2019

Read full article
May 2019
MoCA Accurately and Reliably Differentiates VaD and VMCI from Controls
Read abstract
May 2019
International Journal of Geriatric Psychiatry Confirms MoCA Test Accurately and Reliably Differentiates VaD and VMCI from Controls

Based on the available studies, the MoCA is the most accurate and reliable instrument for identifying VCI.

Read full article
April 2019
MoCA is superior to MMSE in the identification of MCI
Read abstract
March 2019
MoCA: Best Paper and Pencil Test
Read abstract
October 2018
AAN Neurology: Early MoCA predicts long-term cognitive and functional outcome and mortality after stroke
Read abstract
February 2018
Journal of Alzheimer disease: Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study
Read abstract
January 2018
PRNewswire: Trump and MoCA Test : Comments by Dr Ziad Nasreddine Test Creator
Read full article
January 2018
NBC News: Maria Shriver: Why President Trump's cognitive test is a reminder for us all.
Read full article
January 2018
CNN: The MoCA Test: What to Know. This is the cognitive test the president passed.
Read full article
October 2017
MoCA Seen as Most Effective at Measuring Cognitive Problems in Lupus
Read abstract
January 2015
MoCA is Free alternatives comparable to Mini-Mental State Examination
Read abstract
September 2014
MoCA superior to MMSE in Vascular Cognitive Impairment associated with Hypertension
Read abstract
October 2013
MedPage Today : MoCA Beats MMSE to Assess Dementia
Read full article
November 2010
Neurology: The MoCA: well-suited screen for cognitive impairment in Parkinson disease.
Read abstract
September 2006
MoCA Recommended by NIH and CSN for Stroke
Read abstract